KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Depreciation and Depletion (2020 - 2025)

Boston Scientific's Depreciation and Depletion history spans 6 years, with the latest figure at $137.0 million for Q4 2025.

  • For Q4 2025, Depreciation and Depletion rose 12.3% year-over-year to $137.0 million; the TTM value through Dec 2025 reached $471.0 million, up 14.32%, while the annual FY2025 figure was $471.0 million, 14.32% up from the prior year.
  • Depreciation and Depletion for Q4 2025 was $137.0 million at Boston Scientific, up from $117.0 million in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $137.0 million in Q4 2025 and bottomed at $76.0 million in Q1 2022.
  • The 5-year median for Depreciation and Depletion is $94.0 million (2022), against an average of $96.8 million.
  • The largest annual shift saw Depreciation and Depletion fell 8.43% in 2022 before it increased 17.78% in 2025.
  • A 5-year view of Depreciation and Depletion shows it stood at $98.0 million in 2021, then decreased by 3.06% to $95.0 million in 2022, then rose by 9.47% to $104.0 million in 2023, then increased by 17.31% to $122.0 million in 2024, then increased by 12.3% to $137.0 million in 2025.
  • Per Business Quant, the three most recent readings for BSX's Depreciation and Depletion are $137.0 million (Q4 2025), $117.0 million (Q3 2025), and $111.0 million (Q2 2025).